Actively Recruiting
Exploring the Mechanism of Primary Resistance to Third-generation EGFR-TKIs as First-line Treatment in EGFR-positive Advanced NSCLC (PRECISE Study)
Led by Second Xiangya Hospital of Central South University · Updated on 2024-12-02
210
Participants Needed
1
Research Sites
274 weeks
Total Duration
On this page
Sponsors
S
Second Xiangya Hospital of Central South University
Lead Sponsor
X
Xiangya Hospital of Central South University
Collaborating Sponsor
AI-Summary
What this Trial Is About
Lung cancer is currently the world's largest malignant tumor for cancer-related deaths with non-small cell lung cancer (NSCLC) accounting for 80%-85%. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), especially the 3rd-generation EGFR-TKIs have demonstrated strong antitumor effects in EGFR-positive patients. However, approximately 20% of EGFR-positive were primarily resistant to 3rd generation EGFR-TKIs, i.e., clinical non-response or disease progression in the short term. This study aimed to clarify the molecular indicators that predict the benefits of 3-rd EGFR-TKIs as first-line therapy in NSCLCpatients with EGFR-positive. Further, to clarify their primary drug resistance mechanisms, which is of great significance for the treatment and clinical decision-making of NSCLC disease.
CONDITIONS
Official Title
Exploring the Mechanism of Primary Resistance to Third-generation EGFR-TKIs as First-line Treatment in EGFR-positive Advanced NSCLC (PRECISE Study)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age over 18 years
- Diagnosed with non-small cell lung cancer (NSCLC) by tissue or cell analysis
- Clinical stage IIIB to IV that cannot be removed by surgery or has recurrence/metastasis after surgery
- At least one measurable tumor lesion according to standard criteria
- Positive EGFR mutation confirmed by tissue or fluid samples
- Using approved third-generation EGFR-TKIs as first-line treatment for NSCLC
- Willing to provide clinical, imaging data, samples, and follow-up for research
- Agree to participate and sign informed consent
You will not qualify if you...
- Unable to understand or cooperate with the study or refuse to sign consent
- Pregnant or breastfeeding women
- Any other cancer diagnosed within the past 3 years
- Participation in other clinical drug trials
- Received systemic anti-tumor therapy within the past 2 years
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Department of Oncology, The Second Xiangya Hospital, Central South University
Changsha, Hunan, China, 410011
Actively Recruiting
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here